Company Description

ReAx Biotechnologies is leveraging next-generation chemical proteomics to discover, optimize, and validate small molecules directly in cells. Its platform enables the interrogation of proteomic ‘dark matter’—a largely unexplored landscape for ligand discovery—targeting high-value proteins in oncology and immunological diseases. By integrating cutting-edge chemistry, disease biology, and computational methods, ReAx aims to develop first-in-class therapeutics for previously inaccessible targets.